Genmab | GEN - Sales Revenues

Stock Price
2,007.00
Daily Change
-90.00 -4.29%
Monthly
-0.15%
Yearly
43.10%
Q1 Forecast
1,920.90

Genmab reported DKK5.86B in Sales Revenues for its fiscal quarter ending in June of 2025.





Sales Change Date
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
Almirall EUR 560.46M 71.95M Jun/2025
Amarin USD 49.67M 23.07M Sep/2025
Amgen USD 9.9B 340M Dec/2025
argenx SE USD 987.09M 144.59M Sep/2025
AstraZeneca USD 15.19B 733M Sep/2025
Bayer EUR 9.66B 1.08B Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Demant DKK 6.26B 810M Dec/2025
Exelixis USD 597.8M 29.5M Sep/2025
Fresenius Medical Care EUR 4.89B 100M Sep/2025
Galapagos EUR 65.3M 4.87M Sep/2025
Genmab DKK 5.86B 580M Jun/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
GN Store Nord DKK 3.96B 200M Sep/2025
GRIFOLS EUR 1.87B 20M Sep/2025
Hikma Pharmaceutical USD 829M 758M Jun/2025
Insmed USD 142M 34.6M Sep/2025
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.32B 890M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
UCB EUR 3.49B 129M Jun/2025